Summit Therapeutics plc (SMMT)

3.4050 -0.1050 (-2.99%) As of 01:10PM EDT. Market open.

Summit Therapeutics plc

601 Brickell Key Drive
Suite 1000
Miami, FL 33131
United States
650 460 8308
https://www.summittxinc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 105

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Robert W. Duggan	Co-CEO & Executive Chairman	N/A	N/A	1945
Dr. Mahkam Zanganeh D.D.S., M.B.A.	Co-CEO, President & Director	657.81k	N/A	1970
Mr. Manmeet Singh Soni	COO, CFO & Director	591.5k	N/A	1978
Prof. Dame Kay Davies DBE, FRS CBE	Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor	N/A	N/A	1951
Mr. Bhaskar Anand	Chief Accounting Officer & Head of Finance	N/A	N/A	1978
Ms. Abby Guzman Murphy	Head of Human Resources	N/A	N/A	N/A
Ms. Divya Chari	Head of Global Clinical Operations	N/A	N/A	1968
Mr. Dave Gancarz	Chief Business & Strategy Officer?	N/A	N/A	N/A
Mr. Will Black	Head of Information Technology?	N/A	N/A	N/A
Dr. Betty Y. Chang Ph.D.	Head of Research, Oncology & Inflammation?	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Corporate governance

Summit Therapeutics plc’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.